Last reviewed · How we verify
COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose patent landscape — cliff calendar, originator estates, attackable patents
- COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose treatment landscape brief
- COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose treatment updates RSS
Frequently asked questions about COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose
What drugs treat COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose?
Tracked treatments include bivalent BNT162b2 (original/Omi BA.4/BA.5).
What is the treatment for COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose?
Standard treatment for COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose includes bivalent BNT162b2 (original/Omi BA.4/BA.5). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose patent cliff · COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose CI report
- Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing